1. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study 
Dr Raph L Hamers, MD, Carole L Wallis, PhD, Cissy Kityo, MD, Margaret Siwale, MRCP, Kishor Mandaliya, MBChB, Francesca Conradie, MD, Mariette E Botes, MD, Maureen Wellington, MBChB, Prof Akin Osibogun, MD, Kim C E Sigaloff, MD, Immaculate Nankya, PhD, Rob Schuurman, PhD, Ferdinand W Wit, MD, Prof Wendy S Stevens, MMed, Michèle van Vugt, MD, Prof Tobias F Rinke de Wit, PhD 
The Lancet Infectious Diseases 
Volume 11, Issue 10, Pages (October 2011)
DOI: /S (11)
Copyright © 2011 Elsevier Ltd Terms and Conditions

2. Figure 1
Study profile
The Lancet Infectious Diseases  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions

3. Figure 2
Prevalence of HIV-1 primary drug-resistance in antiretroviral-naive individuals in the PASER-M cohort by region and drug class
People with at least one drug-resistance mutation shown as proportion of all people by region and drug class. Regions are clustered by country and sorted by descending calendar year of roll-out of antiretroviral therapy. NRTI=nucleoside reverse transcriptase inhibitor. TAM=thymidine analogue mutation. NNRTI=non-NRTI. PI=protease inhibitor. *Multiclass is resistance to at least two drug classes.
The Lancet Infectious Diseases  , DOI: ( /S (11) )
Copyright © 2011 Elsevier Ltd Terms and Conditions